Summit Therapeutics
34
21
23
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
5.9%
2 terminated/withdrawn out of 34 trials
71.4%
-15.1% vs industry average
21%
7 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (34)
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Role: collaborator
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Role: lead
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Role: collaborator
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Role: collaborator
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Role: lead
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Role: collaborator
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Role: collaborator
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Role: collaborator
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Role: collaborator
A Study of Ivonescimab in People With Leiomyosarcoma
Role: collaborator
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Role: collaborator
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Role: collaborator
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Role: collaborator
Phase III Study of AK112 for NSCLC Patients
Role: lead
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Role: collaborator
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Role: collaborator
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Role: collaborator
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Role: collaborator
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Role: lead
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Role: collaborator